Talk:Viatris

This edit request by an editor with a conflict of interest has now been answered.

Hi. I work for Viatris, and I would like to request the following edit:

• Please add Viatris’ status as a NASDAQ Biotechnology Component^[1][2] to the "Traded as" section in the infobox.

Thank you for your help, PittGuy123ABC (talk) 18:39, 24 February 2022 (UTC)

Hi. I would like to add two more bullet points to this edit request.

• Since I posted the above edit request the company has had an important development in its history which should be added to the article. At the end of the History section, please add the following sentence: "In February 2022, Viatris announced an agreement where it will contribute to Biocon Biologics its biosimilars portfolio and related commercial and operational capabilities in exchange for up to $3.335 billion, including a stake of at least 12.9% in Biocon Biologics."^[3]
• Please add to the Infobox that Viatris is a component of the Russell1000.^[4][5]

Thanks. PittGuy123ABC (talk) 16:31, 9 March 2022 (UTC)

 Done - Suggested edits added - should be ok - Stay Safe and Healthy !! - Drbogdan (talk) 14:43, 24 March 2022 (UTC)

Hi Drbogdan. Thank you so much for your quick help with my edit request. Two small questions:

1. It seems that you mistakenly changed the company’s stock symbol to VTR which is the symbol for a similarly-named company. Could you please change this back to the correct symbol of VTRS?
2. Because I made this request in two stages, it seems that the first part of my request went unnoticed. To restate that request here, could you please add Viatris’ status as a NASDAQ Biotechnology Component^[6][7] to the "Traded as" section in the infobox?

Thanks again. PittGuy123ABC (talk) 15:59, 24 March 2022 (UTC)

 Done - @PittGuy123ABC: Thanks for your upd suggestions - should now be better - iac - Stay Safe and Healthy !! - Drbogdan (talk) 17:21, 24 March 2022 (UTC)

It looks like this request has been answered, so I am closing this as answered. Z1720 (talk) 01:24, 3 April 2022 (UTC)

This edit request by an editor with a conflict of interest has now been answered.

Hi Drbogdan. Thanks so much for implementing my previous edit request. I have one additional request as follows: Please add the following sentence to the end of the "Products" section. "Breyna (Budesonide and Formoterol Fumarate Dihydrate Inhalation Aerosol) received approval from the US FDA in March 2022 as the first generic version of Symbicort for the treatment of asthma and COPD.^[1][2] "

Thanks again. PittGuy123ABC (talk) 18:20, 28 March 2022 (UTC)

 Done - Stay Safe and Healthy !! - Drbogdan (talk) 19:09, 28 March 2022 (UTC)

Request has been answered, so I am closing this. Z1720 (talk) 01:25, 3 April 2022 (UTC)

This edit request by an editor with a conflict of interest has now been answered.

Hi. I saw that editor XyZAn recently added a sentence about Viatris's announcement of their agreement to acquire Oyster Point Pharma and Famy Life Sciences. I thank XyZAn for the addition, but I wonder if someone could slightly tweak the sentence to add information about the new division the company will create as a result of the planned acquisitions with a new, third-party source. The new sentence I propose is as follows:

In November 2022, Viatris announced agreements to acquire Oyster Point Pharma and Famy Life Sciences for a total of $700-$750 million in cash to create an ophthalmology division.^[1]

Also, since the acquisitions haven't yet been finalized, I think it would be most appropriate to remove the companies from the chart of Viatris's acquisitions until the deals are (hopefully) completed as planned in early 2023.

Thanks so much, PittGuy123ABC (talk) 16:33, 10 November 2022 (UTC)

 Done Ptrnext (talk) 22:26, 11 November 2022 (UTC)

Thanks so much Ptrnext for your quick response and edits. PittGuy123ABC (talk) 18:18, 23 November 2022 (UTC)

This edit request by an editor with a conflict of interest has now been answered.

Hi again. I would like to have some updates made to the page that reflect the finalization of recent deals, plus a few other edits so that the article is as current as possible.

• In the "History" section, add the following directly after the first sentence of the last paragraph, which ends with "including a stake of at least 12.9% in Biocon Biologics.":

The transaction was completed in November 2022.^[1]

• In the "History" section, add the following directly after the last sentence which begins "In November 2022,":

The acquisitions closed in January 2023.^[2][3]

• Please remove the (Acq pending) from Oyster Point Pharma and Famy Life Sciences on the "Viatris Acquisitions" chart, and replace with (Acq 2023) for both.
• In the Infobox, please add the parameter "Subsidiaries" and list "Oyster Point Pharma" and "Famy Life Sciences" as the subsidiaries.
• Finally, Please add the following sentence to the end of the History section:

In 2022, Viatris was recognized by Forbes as one of the world's best employers^[4] and by Newsweek as one of America's most responsible companies.^[5]

I am pinging Drbogdan who has helped here in the past. Thanks. PittGuy123ABC (talk) 18:18, 22 February 2023 (UTC)

 Done - @PittGuy123ABC: - newly installed edits seem ok - Stay Safe and Healthy !! - Drbogdan (talk) 19:40, 22 February 2023 (UTC)

Thanks so much for your help. You should stay safe and healthy, too. PittGuy123ABC (talk) 13:20, 23 February 2023 (UTC)

This edit request by an editor with a conflict of interest has now been answered.

Hello, I would like to update the page with information about the new CEO.

1. In the infobox, under Key people, please delete Michael Goettler and replace him with Scott A. Smith (CEO). Also delete Ian Read, as he is now retired as Director.
2. At the end of the History section, please add: On April 1, 2023, Scott A. Smith became Viatris' CEO, succeeding Michael Goettler. Smith previously served on the company's board since 2022. ^[1]

Once again pinging Drbogdan who has been so helpful with previous requests. Thank you. PittGuy123ABC (talk) 16:09, 3 April 2023 (UTC)

 Done @PittGuy123ABC: (and others) - Updated with edit suggestions - Should now be ok - Stay Safe and Healthy !!- Drbogdan (talk) 16:45, 3 April 2023 (UTC)

Drbogdan, thank you once again for your help in updating the page! PittGuy123ABC (talk) 17:50, 5 April 2023 (UTC)

This edit request by an editor with a conflict of interest has now been answered.

Hi. In order to keep the article up-to-date, please add the following sentences to the end of the History section but before the Predecessors sub-section:

In April 2023, Viatris was recognized by LinkedIn as one of the 25 best companies to work for in India,^[1] and one of the 25 best companies offering career development in Ireland.^[2]

In May 2023, USA Today included Viatris in its list of 400 US companies who have reduced their greenhouse gas emissions intensity from 2019 to 2021. ^[3]

In June 2023, Viatris was named to the Forbes Global 2000 list of the world's largest companies.^[4]

Pinging Drbogdan to help with this edit. Thanks so much, PittGuy123ABC (talk) 13:43, 21 June 2023 (UTC)

 Done - ok - added suggested text/refs to the main article - Stay Safe and Healthy !! - Drbogdan (talk) 14:36, 21 June 2023 (UTC)

Closing request per above. Z1720 (talk) 16:37, 22 June 2023 (UTC)

Thanks so much Drbogdan for your quick and helpful response. I took the liberty of closing the edit request. Wishing you good health and safety, too. PittGuy123ABC (talk) 14:37, 26 June 2023 (UTC)

This edit request by an editor with a conflict of interest has now been answered.

Hi. Can you kindly make the following changes to the History and Products sections, as follows:

• In the sixth paragraph in the History section that begins "In 2022, Viatris was recognized…" Please add the bolded words to update the sentence to the following:

In 2022 and 2023, Viatris was recognized by Forbes as one of the world's best employers. ^{[1] [2]} Also in 2022, Newsweek recognized Viatris as one of America's most responsible companies. ^[3]

• Please add the following update to the end of the History section:

In October 2023, Viatris reached agreements to divest from almost all of its OTC business, its women’s healthcare business, and its India-based active pharmaceutical ingredients business for a total of about $3.6 billion.^[4]

• Please replace the list of products in the "Products" section with the following list. The new list is in chronological order, adds newly available products, and removes products which Viatris no longer sells.

• Dolutegravir: In December 2020, received FDA approval to treat children with HIV/AIDS in low to middle income countries. The formulation is strawberry-flavored to make it easier to give to children and was made available at a 75% discount compared to previous treatments.^[5][6]
• Breyna (Budesonide and Formoterol Fumarate Dihydrate Inhalation Aerosol): In March 2022, received approval from the US FDA in March 2022 as the first generic version of Symbicort for the treatment of asthma and COPD.^[7][8]
• GA Depot (long-acting version of Glatiramer acetate): In August 2023, received New Drug Application acceptance from the US FDA as a once-monthly injection for the treatment of relapsing forms of multiple sclerosis.^[9][10]
• Abacavir/dolutegravir/lamivudine: In September 2023, received tentative US FDA approval for a New Drug Application through the President's Emergency Plan for AIDS Relief (PEPFAR) for the treatment of HIV-1 infection in pediatric patients.^[11][12]
• Ryzumvi(phentolamine ophthalmic solution 0.75%): In September 2023, received FDA approval for the treatment of mydriasis caused by adrenergic agonist or parasympatholytic agents or a combination of those drugs. It was previously known as Nyxol.^[13]

Thanks so much. Once again pinging Drbogdan who often steps up to help with editing this page. PittGuy123ABC (talk) 15:33, 1 February 2024 (UTC)

• I take a dim view of any and all "best company" rankings, but the Newsweek one is not acceptable because Newsweek is not considered a reliable source on English Wikipedia. (t · c) buidhe 16:09, 1 February 2024 (UTC)

 Done Klbrain (talk) 00:08, 28 March 2024 (UTC)

Thank you Klbrain for your help with these changes. I appreciate your prompt response and implementation. Best regards. PittGuy123ABC (talk) 15:00, 28 March 2024 (UTC)

This edit request by an editor with a conflict of interest has now been answered.

Hello. Please add the following update to the end of the Partnerships section.

In February 2024, Viatris entered into an agreement with Idorsia to collaborate on global research and development and the commercialization rights to Phase 3 pharmaceuticals selatogrel, a cardiac medication, and cenerimod, a novel immunology medication used to treat systemic lupus erythematosus. The agreement includes the potential to add more assets in the future.^[1][2][3]

Pinging Drbogdan who has helped here before. Thanks so much. PittGuy123ABC (talk) 18:11, 29 May 2024 (UTC)

 Done should now be ok - comment if otherwise of course - iac - Stay Safe and Healthy !! - Drbogdan (talk) 18:56, 29 May 2024 (UTC)

Hi Drbogdan. Thanks so much for implementing the edit request. All the best, PittGuy123ABC (talk) 17:16, 18 June 2024 (UTC)

Hello. Could you kindly make the following edits to update the History section?

• In the sixth paragraph in the History section that begins "In 2022 and 2024…" please the years to the following, which are correct:

In 2021, 2022, and 2023,^[1] Viatris was recognized by Forbes…"

• Please add the following to the beginning of the ninth paragraph which begins: "In May 2023, USA Today included Viatris…"

In May 2024, USA Today included Viatris in its list of 450 US -based companies that have reduced their greenhouse gas emissions between 2020 and 2022.^[2]

• At the end of the History section, please add the following:

In June 2024, Time magazine included Viatris in its list of the world's 500 Most Sustainable Companies.^[3]

Pinging Klbrain who implemented a previous edit request. Thanks so much. PittGuy123ABC (talk) 15:43, 16 August 2024 (UTC)

Hi. I would like to request that the content in the newly created Controversies section be re-written to better reflect the issue according to acceptable third-party sources, in place of the sources used now, which are: a primary source; a source that does not mention Viatris; and a press release. Also, please move the re-written content to the end of the History section and delete the Controversy section to avoid WP:CSECTION and WP:UNDUE.

In late December 2024, Viatris disclosed that the US FDA issued a warning letter and an import alert concerning the company's drug-making facility in Indore, India. The import alert affects 11 actively distributed products that will no longer be accepted into the U.S. until the warning letter is lifted. The company announced that it has taken corrective and preventative actions.^[1]

Pinging Klbrain who has helped with edits here before. Thank you. PittGuy123ABC (talk) 19:10, 13 January 2025 (UTC)

I'm happy to make the addition, but the other references look fine. Primary sources can be used to support statements of fact, if they're in support of independent sources (as they are here); it's true that the biospectrumindia reference doesn't mention Viatris, but the claim it supports does not relate to Viatris - it relates to "a recurrent theme within FDA inspection of the Pharmaceutical industry in India". So, added the last sentence (with reference), but not changed the other text. Klbrain (talk) 20:36, 13 January 2025 (UTC)

Thanks Klbrain for addressing this issue. My main concern is with the addition of an entire new "Controversies" section based on this one story. As I stated above, Wikipedia best practices discourage the use of "Controversy" sections in order to maintain a neutral point of view. Adding such a section here gives WP:UNDUE weight to a story that should be rolled into the History section, as I suggested above. I think there may be some confusion regarding the sourcing as well, but I'll look into that further and bring it back to the community when relevant. Thanks again for your help. ~~~~ PittGuy123ABC (talk) 13:58, 14 January 2025 (UTC)

Fair point re new section; I've moved the paragraphy up to 'History' and removed the heading (noting the NPOV); I'm not sure that the thrust of the content undue, although the aside about other companies might be considered as 'off topic'. Klbrain (talk) 16:14, 14 January 2025 (UTC)

Hi Klbrain. Thanks again for your fast response and implementation of my request to move the content to History. I wonder if you would kindly reconsider my version of the paragraph in place of the current paragraph. My version is more concise, including only the most important details that relate to the issue, taken directly from a reliable third-party source. There is no reason to include "following a 9-day inspection" and "FDA Establishment Identifier:FEI 3010453141," and a few other details. And as you mentioned above, an "aside about other companies" is also not needed. For your convenience, here is the version I had posted above:

In late December 2024, Viatris disclosed that the US FDA issued a warning letter and an import alert concerning the company's drug-making facility in Indore, India. The import alert affects 11 actively distributed products that will no longer be accepted into the U.S. until the warning letter is lifted. The company announced that it has taken corrective and preventative actions.^[1]

If you have any concerns or questions, please feel free to ask. And thanks again for all your help. PittGuy123ABC (talk) 16:13, 16 January 2025 (UTC)

Hello. The last paragraph of the History section includes some information not relevant to the main subject of the paragraph. I would like to suggest a version to replace the paragraph, which is more concise and includes only the most important details about the issue, relying on a reliable third-party source in place of a press release and a primary source. Kindly replace the last paragraph of the History section with the following:

In late December 2024, Viatris disclosed that the US FDA issued a warning letter and an import alert concerning the company's drug-making facility in Indore, India. The import alert affects 11 actively distributed products that will no longer be accepted into the U.S. until the warning letter is lifted. The company announced that it has taken corrective and preventative actions.^[2]

Thanks for taking the time to consider this edit request. ~~~~ PittGuy123ABC (talk) 13:43, 30 January 2025 (UTC)